AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
Key takeaways
- Tezspire’s strong Phase 3 results could open a new revenue stream for AZN and AMGN in the EoE market.
- 64.8% histologic remission (210 mg, 24 weeks)
- 68.9% histologic remission (420 mg, 24 weeks)
- 3.5% remission (placebo, 24 weeks)
What happened
AstraZeneca Plc (AZN) and Amgen Inc. (AMGN) announced that their drug Tezspire (tezepelumab) achieved significant clinical success in a Phase 3 trial for eosinophilic esophagitis (EoE). In the CROSSING study, both 210 mg and 420 mg doses met the co‑primary endpoints, showing high rates of histologic remission and reduced swallowing difficulty at 24 weeks, with benefits lasting through 52 weeks.
Why it matters
The results suggest Tezspire could become a first‑in‑class treatment for EoE, a disease with limited options. High remission rates (up to 68.9 % at 24 weeks) and durable symptom relief may drive future sales and broaden the drug’s commercial scope beyond asthma and chronic rhinosinusitis. Positive data also support…
Short-term and longer-term
Short-term. Over the next few days, traders should watch for any earnings guidance updates that incorporate Tezspire’s potential sales.
Longer-term. For investors, the data reinforce Tezspire’s commercial upside and could justify a longer‑term investment thesis.